As reported at previous conferences, the antibody managed to remove amyloid plaques quickly while triggering but a ... split equally into four ascending dose groups, then added a dose-expansion study ...

Analysis of this data set revealed that removal of brain amyloid plaques years before symptoms ... extension and expansion of this genuinely unprecedented and groundbreaking research, and we ...

This expansion reflects LMI's commitment to ensuring broad ... imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated ...

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the drugs bind to toxic amyloid beta protein to tackle the disease. Using new ...

Panelists discuss how managing patients with mild cognitive impairment using amyloid-targeting therapies faces significant barriers including limited healthcare infrastructure for complex diagnostic ...

Panelists discuss how amyloid-targeting therapies for Alzheimer disease represent a breakthrough drug class that works by binding to and removing beta-amyloid plaques through various mechanisms ...

Preliminary results for trontinemab from 114 participants in the 1.8 or 3.6 mg/kg double-blind period suggest rapid and deep, dose-dependent reduction of amyloid plaques in the brain as measured ...

As reported at previous conferences, the antibody managed to remove amyloid plaques quickly while triggering but a ... split equally into four ascending dose groups, then added a dose-expansion study ...

This expansion reflects LMI's commitment to ensuring ... Errors may occur in the Neuraceq estimation of brain neuritic β-amyloid plaque density during image interpretation. Image interpretation ...